- Home
- EPIX vs CRDL Comparison
EPIX vs CRDL Comparison
Compare EPIX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- CRDL
- Stock Information
- Founded
- EPIX 2009
- CRDL 2017
- Country
- EPIX Canada
- CRDL Canada
- Employees
- EPIX N/A
- CRDL N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPIX Health Care
- CRDL Health Care
- Exchange
- EPIX Nasdaq
- CRDL Nasdaq
- Market Cap
- EPIX 75.9M
- CRDL 80.1M
- IPO Year
- EPIX N/A
- CRDL N/A
- Fundamental
- Price
- EPIX $1.72
- CRDL $1.24
- Analyst Decision
- EPIX Hold
- CRDL Strong Buy
- Analyst Count
- EPIX 3
- CRDL 3
- Target Price
- EPIX $2.00
- CRDL $9.33
- AVG Volume (30 Days)
- EPIX 68.7K
- CRDL 250.7K
- Earning Date
- EPIX 08-04-2025
- CRDL 08-11-2025
- Dividend Yield
- EPIX N/A
- CRDL N/A
- EPS Growth
- EPIX N/A
- CRDL N/A
- EPS
- EPIX N/A
- CRDL N/A
- Revenue
- EPIX N/A
- CRDL N/A
- Revenue This Year
- EPIX N/A
- CRDL N/A
- Revenue Next Year
- EPIX N/A
- CRDL N/A
- P/E Ratio
- EPIX N/A
- CRDL N/A
- Revenue Growth
- EPIX N/A
- CRDL N/A
- 52 Week Low
- EPIX $1.40
- CRDL $0.77
- 52 Week High
- EPIX $7.88
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- EPIX 55.34
- CRDL 45.66
- Support Level
- EPIX $1.60
- CRDL $1.35
- Resistance Level
- EPIX $1.73
- CRDL $1.50
- Average True Range (ATR)
- EPIX 0.04
- CRDL 0.10
- MACD
- EPIX 0.00
- CRDL -0.02
- Stochastic Oscillator
- EPIX 76.50
- CRDL 18.50
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.